EDGAR·FLOW

Unicycive Therapeutics, Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 8/100
What the filing says
CEO Shalabh Gupta and CFO John Townsend certified the Q3 2026 10-Q (period ended September 30, 2026, filed November 16, 2026) under SOX §302 and §906, attesting that financial statements fairly present the company's condition and that disclosure controls are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating

Routine SOX certification exhibits; no substantive business information disclosed. Standard compliance document.

View original filing on SEC.gov ↗ UNCY · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.